All News
Guan et al. Accuracy of financial disclosures in rheumatology journals. 76% papers >=1 inaccuracy. 78% authors >= undisclosed/underreported COI. Worse in clinical trials 85% @RheumNow #ACR22 Abstr#1267 https://t.co/dmqp3sj11f https://t.co/UXQgUCcGWb
Richard Conway RichardPAConway ( View Tweet)
What are we treating PMR with?
RISE registry, 2016-20 (n=26,102 in US)
- Such a small proportion ever see non-steroid therapies
- Big chunk remain on steroids or lost to follow-up
Surely we can improve PMR care!
ABST1546 @SattuiSEMD @RADoctor #ACR22 @RheumNow https://t.co/Ocuw5WxKu2
David Liew drdavidliew ( View Tweet)
Don't stop HCQ even after ESRD occurs in #LupusNephritis!
1578 pts w/ESRD on HCQ only, GCs only or HCQ+GCs (n=509). HCQ groups had lower cardiac complications & infx compared to steroid only group. No diff. in thrombosis & all-cause mortality. #ACR22 @rheumnow #ACRbest abst#0539
TheDaoIndex KDAO2011 ( View Tweet)
Lee et al. 55% of requested cryoglobulin tests not successfully completed. @RheumNow #ACR22 Abstr#1281 https://t.co/QLCEFueeHi https://t.co/toEUukyXQf
Richard Conway RichardPAConway ( View Tweet)
Higher NSAID intake is assoc'd w/ lower radiographic spinal progression, particularly in r-axSpA patients. COX2i might have stronger inhibitory effect on radiographic progression compared to NS-NSAIDs. @ProftDr @RheumNow Abs 1492 #ACR22 https://t.co/l51wMqm5fB https://t.co/UaBCRRSJEE
Dr. Rachel Tate uptoTate ( View Tweet)
Subclinical GCA in PMR
🌟US findings of GCA in 22% PMR pts w/o signs or symptoms of GCA
🔥Different US pattern vs classical GCA
Subclinical GCA:
👉predilection extra-cranial arteries
👉⬆️ IMT of large vessels
#ACR22 @RheumNow Abst#1619 https://t.co/HV9dsTBfg8
Patricia Harkins DrTrishHarkins ( View Tweet)
Nurses’ Health Study - 34 yr f/u data #gout
- women with gout have ⬆️ risk of all-cause mortality,
- primarily driven by ⬆️ risk of CVD deaths.
#ACR22 @rheumnow abst#1757 https://t.co/K2ykelHAlL
Bella Mehta bella_mehta ( View Tweet)
13S150. Draft ACR/EULAR APLS Classif Criteria
⭐️Reminder: Classification = high specificity, not Diagnostic Crit!
⭐️Previously Sapporo: clinical (vasc/preg) + immunologic
-- Lack of risk stratification, unclear definition of aPL+, no valvulopathy, outdated pregnancy
@Rheumnow
Eric Dein ericdeinmd ( View Tweet)
Izokibep, a new IL-17Ai, demonstrated efficacy in treatment of psoriatic arthritis in a phase 2 study with a safety profile similar to other IL-17i.
Abs#1597 @RheumNow #ACR22 https://t.co/3LA9u8NsC4
Robert B Chao, MD doctorRBC ( View Tweet)
#ACR22 Abstr#0957 Do women with Anti-Ro/La+ get 1st screening for congenital heart block via foetal echo in time (16-18 wks)? A cohort study in 44 pregnancies found only 32% had =<18wks. 5 CHB detected (3 in 1st screening which was >19wks. This needs to improve @RheumNow https://t.co/dqJCCSwGLx
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Increasing fracture incidence rates for both AS and comparator groups. Increased in the TNFi era (2004-2021) relative to the pre-TNFi era (2000-2003). The ratio (AS/comparators) appear stable over the past 2 decades
Merjanah S Abs1911 https://t.co/lLtW4eh0nm #ACR22 @RheumNow https://t.co/1Nr6ru1vPv
Dr. Antoni Chan synovialjoints ( View Tweet)
Tune in to Twitter, Facebook or LinkedIn daily at 5pm ET. Catch our daily recap LIVE! #ACR22 https://t.co/fgwqIjuXJ4
Dr. John Cush RheumNow ( View Tweet)
Lifestyle modifications can affect tx response with TNFi in axSpA!
Accdg to this study fr Prof GJones, ✳️Smokers, overwt & obese pts are ⬇️ likely to achieve treatment response to TNFi vs. nonsmokers & normal wt pts
Smoking cessation, wt mgt is key!
#ACR22 @RheumNow ABST#1510 https://t.co/PBFcj6zKVD
sheila RHEUMarampa ( View Tweet)
De Craemer et al. Local vs Central reading of images. Rheumatologists overcall sacroiliitis on both plain films and MRI in ?AxSpA . ? some of this out of a desire to try something to help someone who is suffering @RheumNow #ACR22 Abstr#1255 https://t.co/j89E0sUPmN https://t.co/Ez5ldSSQJl
Richard Conway RichardPAConway ( View Tweet)
Ramahi @sclerodermaUM et al Risk factors for ILD decline in SSc. Anti-Topoisomerase I only identified factor in multivariable model. @RheumNow #ACR22 Abstr#1524 https://t.co/lc2BPjgqiC https://t.co/qx3M6dfd3w
Richard Conway RichardPAConway ( View Tweet)
Plenary:
Tyrosine kinase 2 (TYK2)
◦ Mediates signaling of Type I IFNs, IL-23, and IL-12
◦ Key cytokines involved in lupus pathogenesis
◦ Deucravacitinib oral TYK2 inhibitor
◦ Phase 2 RCT in SLE showed efficacy
Pike M Abs1117 https://t.co/eJhNsM02Vl #ACR22 @RheumNow https://t.co/C6JQqR1DLj
Dr. Antoni Chan synovialjoints ( View Tweet)
Doyen et al. FIND-RA study. RA for >1<10 years. RA-ILD 12%, air trapping 58%, rheumatoid nodules 11%. @RheumNow #ACR22 Abstr#1393 https://t.co/Sy1qwZJq5E https://t.co/ww8HgHT32E
Richard Conway RichardPAConway ( View Tweet)
There is an association between the severity of skin and joint or axial disease, both at baseline and longitudinally, in pts presenting w/in 12 months of diagnosis of PsA. Abs 1511 #ACR22 @RheumNow https://t.co/PcVn6dITqU https://t.co/qxn3LBOW8d
Dr. Rachel Tate uptoTate ( View Tweet)
Sanchez Martin et al. Assessing effect tocilizumab by PET in GCA. Vascular involvement not generally fully controlled by tocilizumab. Not sure how PET was scored here. @RheumNow #ACR22 Abstr#1257 https://t.co/cGEoScnPb3 https://t.co/W0yYMPMjni
Richard Conway RichardPAConway ( View Tweet)
Yen et al. Taiwanese study of risk of MACE in SSc. No difference in MACE IRR 1.15 (95%CI 0.87–1.52) or stroke IRR 0.89 (95%CI 0.61-1.29), increase in MI IRR 1.76 (95%CI 1.08-2.86) @RheumNow #ACR22 Abstr#1191 https://t.co/3BiTLafGmk https://t.co/IManEvAh47
Richard Conway RichardPAConway ( View Tweet)